YOLFTbeta
Relmada Therapeutics Inc

Relmada Therapeutics Inc

RLMD · NASDAQ · Healthcare / Biotechnology

4.21USD+0.05 (+1.20%)

Price History

Full chart

Market Stats

Previous Close4.16
Open4.70
Day Range3.82 – 4.71
52-Week Range1.80 – 8.00
Volume1.74M
Market Cap408.55M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.91
Dividend Yield0.00%
Beta0.45
50-Day Avg4.70
200-Day Avg5.47

About

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sergio Traversa M.B.A., Pharm.D.
  • Employees17
  • Headquarters2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134, USA
  • Websitehttps://www.relmada.com

Leadership

  • Dr. Sergio Traversa M.B.A., Pharm.D.CEO & Director · b. 1960
  • Mr. Maged S. Shenouda M.B.A., R.Ph.Chief Financial Officer · b. 1964
  • Mr. Paul E. Kelly M.B.A.COO & Director · b. 1957
  • Mr. Charles S. Ence CPA, M.B.A.Chief Accounting & Compliance Officer · b. 1965
  • Ms. Gina DiGuglielmoVP & Head of Clinical Operations

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.94K5.13K----0-000000
Growth (%)--35.41%------------
Cost of Revenue5.80K4.04K-9.26K54.82K85.27K2.63K4.87K3.75K1.26K----
Gross Profit2.14K1.09K--9.26K-54.82K-85.27K-2.63K-4.87K-3.75K-1.26K----
Gross Margin26.97%21.31%------------
Operating Expense14.19K46.11K-17.09M16.16M7.13M6.91M15.10M60.83M125.70M----
Operating Income-12.05K-45.02K-17.10M-17.10M-16.22M-7.22M-6.92M-15.11M-60.84M-125.70M-161.25M-103.70M-83.89M-59.10M
Operating Margin-151.77%-877.66%------------
EBITDA-11.68K-45.02K-20.79M-17.09M-16.03M-6.92M-6.92M-15.11M-59.33M-125.75M-157.04M4.91M-79.98M-57.39M
EBITDA Margin-147.02%-877.66%------------
Net Income-12.05K-45.02K-20.80M-20.80M-2.98M-6.29M-8.96M-15.01M-59.46M-125.75M-157.04M-98.79M-79.98M-57.39M
Net Income Margin-151.77%-877.66%------------
R&D-5.38M7.87M7.87M6.21M1.29M2.94M7.86M35.97M90.62M113.32M54.81M46.18M744.56K
R&D as % of Total Revenue-104895.24%------------
Interest Expense--4.92K4.92K-5501.34M-1.40M48.32K4.21M---

Balance Sheet

Currency: USD2012-12-312013-12-312014-06-302014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.35K25.76M25.76M24.39M24.39M10.24M2.84M3.05M117.14M118.19M223.33M152.91M97.55M45.82M94.00M
Total Liabilities7.00K26.87M26.87M15.58M15.58M3.20M1.38M8.56M1.46M12.60M15.06M12.47M12.19M10.30M7.49M
Total Equity11.36K-55.28M-1.11M8.81M8.81M7.04M1.46M-5.51M115.68M105.58M208.26M140.44M85.36M35.52M86.51M
Cash8.95K25.56M25.56M22.47M22.47M8.50M1.71M2.24M36.28M2.50M44.44M5.40M4.09M3.86M3.50M
Total Debt-58.36K760.00K263.75K263.75K273.67K2.93M2.94M110.25K------
Net Debt-8.95K-25.51M-25.56M-22.21M-22.21M-8.23M-1.43M702.68K-36.17M-2.50M-44.44M-5.40M-4.09M-3.86M-3.50M

Cash Flow

Currency: USD2012-12-312013-12-312014-06-302014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.57K-11.86K-2.24M-16.23M-16.23M-13.14M-6.47M-6.00M-12.09K-27.81M-91.87M-103.80M-51.66M-51.76M-45.79M
Investing Cash Flow--1.80K-12.54K-23.33K-23.33K-562.26K-49.69K-12.39K-80.16K-34.45M-54.12M19.73M50.45M51.56M-48.14M
Financing Cash Flow13.50K20.00K4.00M13.16M13.16M-263.75K-273.67K6.54M126.11K28.47M187.94M45.02M-98.46K-40.34K93.56M
Capital Expenditure01.80K10.00K23.33K23.33K562.26K49.69K12.39K0053400
Free Cash Flow-7.57K-13.66K-2.25M-16.25M-16.25M-13.71M-6.52M-6.01M-12.09K-27.81M-91.87M-103.80M-51.66M-51.76M-45.79M
FCF to OCF100.00%115.18%100.45%100.14%100.14%104.28%100.77%100.21%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateNov 7, 2014Feb 13, 2015May 19, 2015Sep 11, 2015Nov 6, 2015Feb 5, 2016May 9, 2016Sep 9, 2016Nov 10, 2016Feb 10, 2017May 15, 2017Sep 28, 2017Nov 14, 2017Feb 12, 2018May 14, 2018Sep 28, 2018Nov 13, 2018Feb 13, 2019May 15, 2019Sep 24, 2019Nov 13, 2019Mar 26, 2020May 15, 2020Aug 12, 2020Nov 12, 2020Mar 23, 2021May 12, 2021Aug 10, 2021Nov 11, 2021Mar 23, 2022May 5, 2022Aug 11, 2022Nov 10, 2022Mar 23, 2023May 11, 2023Aug 8, 2023Nov 8, 2023Mar 19, 2024May 8, 2024Aug 7, 2024Nov 7, 2024Mar 17, 2025May 12, 2025Aug 7, 2025Nov 13, 2025Mar 19, 2026May 13, 2026Aug 6, 2026Nov 12, 2026
EPS Estimate-0.40-2.20--1.80--1.68-1.56-0.68--1.68----------0.00-0.36-0.37-0.62-0.94-1.16-1.42-1.47-1.55-1.83-1.22-1.32-1.47-1.33-0.89-0.90-0.91-0.83-0.86-0.83-0.64-0.70-0.31-0.25-0.04-0.14-0.20-0.21-0.14
EPS Actual-14.601.60-0.922.250.36-0.88-0.60-1.00-0.55-0.34-0.66-0.52-0.31-0.46-0.26-0.27-0.27-0.28-0.08-0.50-0.38-0.39-0.66-0.81-1.05-1.31-1.33-1.53-2.42-1.80-1.40-1.08-1.26-1.41-0.87-0.84-0.73-0.84-0.72-0.59-0.72-0.62-0.58-0.30-0.30-0.29-0.22-0.11-
Surprise-3550.00%172.73%-225.00%-47.62%61.54%-47.06%-79.61%------------8.33%-78.38%-30.65%-11.70%-12.93%6.34%-4.08%-56.13%1.64%-14.75%18.18%14.29%-6.01%2.25%6.67%19.78%-1.20%16.28%28.92%-12.50%11.43%-87.10%-20.00%-650.00%-107.14%-12.82%47.62%-
TimingAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap408.55M
Enterprise Value185.48M
Trailing P/E0.00
Forward P/E0.00
Price / Sales9001.90
Price / Book1.95
EPS-0.91
Book Value1.94
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-13.86M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-55.66%
Return on Assets-32.39%
Shares Outstanding106.67M
Shares Float82.64M
Beta0.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 3 analystsTarget 10.75
  • Hold
    3

Ownership Breakdown

Institutions
94.65%
Insiders
3.23%
Retail / Other
2.12%

Top Institutional Holders

  • HHG PLC
    11.06M10.37%
  • Squadron Capital Management LLC
    7.35M6.89%
  • Spruce Street Capital LP
    6.39M5.99%
  • VR Adviser, LLC
    4.84M4.54%
  • Adage Capital Partners Gp LLC
    4.76M4.47%
  • Orbimed Advisors LLC
    4.72M4.42%
  • Marshall Wace Asset Management Ltd
    4.48M4.20%
  • Jones Hill Capital LP
    3.66M3.43%
  • Vanguard Capital Management, LLC
    3.08M2.88%
  • RA Capital Management, LLC
    2.95M2.76%
  • Ikarian Capital, LLC
    2.69M2.52%
  • Millennium Management LLC
    2.36M2.21%
  • Driehaus Capital Management LLC
    2.13M2.00%
  • Eventide Asset Management, LLC
    1.86M1.74%
  • Ameriprise Financial Inc
    1.59M1.49%
  • Polar Capital Holdings PLC
    1.41M1.33%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.17M2.97%
  • iShares Russell 2000 ETF
    2.40M2.25%
  • Eventide Healthcare & Life Sciences I
    1.86M1.74%
  • Franklin Biotechnology Discv A(acc)USD
    1.46M1.37%

Stock Splits

  • Sep 30, 20191:4
  • Aug 12, 20151:5